A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae in Japan
- 17 February 2021
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (3)
- https://doi.org/10.1128/aac.01483-20
Abstract
IMP-type carbapenemase, found in various Gram-negative bacteria, has been increasingly detected worldwide. We aimed to study the outcomes and risk factors for acquisition of IMP-type carbapenemase-producing carbapenem-resistant Enterobacteriaceae (IMP-CRE), as this has not been evaluated in detail. We conducted a matched case-case-control study of patients from whom IMP-CRE isolates were obtained. All patients who tested positive for IMP-CRE were included and matched with those having carbapenem-susceptible Enterobacteriaceae (CSE) and with controls at a ratio of 1:1:2. The risk factors for acquisition between CRE and CSE groups, and mortality which were calculated using multivariate logistic regression model with weighting according to the inverse probability of propensity scores were compared. In total, 192 patients (96 CRE and CSE each; 130 Enterobacter cloacae and 62 Klebsiella spp.) were included. IMP-11 type was present in 43 patients, IMP-1 in 33, and IMP-60 and IMP-66 in 1; 31 (32.3%) patients with CRE and 34 (35.4%) with CSE developed infections. Multivariate analysis identified the following independent risk factors: gastrostomy, history of intravenous therapy or hemodialysis, and previous exposure to broad spectrum β-lactam antibiotics, including penicillin with β-lactamase inhibitors, cephalosporins, and carbapenems. On propensity score-adjusted analysis, mortality in the CRE and CSE groups (15.0% versus 19.5%, respectively) were similar. We found that IMP-CRE may not contribute to worsened clinical outcomes compared to CSE, and gastrostomy, previous intravenous therapy, hemodialysis, and broad-spectrum antimicrobial exposure were identified as risk factors for CRE isolation. Fluoroquinolone and aminoglycosides are potentially useful antibiotics for IMP-CRE infections.Keywords
Funding Information
- International Health Research from the Ministry of Health, Labor and Welfare of Japan (28S-1106)
- MEXT | Japan Society for the Promotion of Science (JP19K19450)
This publication has 29 references indexed in Scilit:
- Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: Systematic review and meta-analysisJournal of Infection, 2018
- Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae at a Turkish centre: Is the increase of resistance a threat for Europe?Journal of Global Antimicrobial Resistance, 2017
- In-vivo loss of carbapenem resistance by extensively drug-resistant Klebsiella pneumoniae during treatment via porin expression modificationScientific Reports, 2017
- The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global MenaceThe Journal of Infectious Diseases, 2017
- Characterization of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae from a healthcare region in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2016
- Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter speciesClinical Microbiology & Infection, 2014
- Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of CarbapenemsAntimicrobial Agents and Chemotherapy, 2014
- Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global DimensionsClinical Microbiology Reviews, 2012
- Global Spread of Carbapenemase-producingEnterobacteriaceaeEmerging Infectious Diseases, 2011
- Metallo-β-lactamases: a last frontier for β-lactams?The Lancet Infectious Diseases, 2011